Verrica Pharmaceuticals Inc. (VRCA) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts VRCA Hot Sheet
Join SI Premium – FREE
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q4 EPS of ($0.53), $0.05 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $1.98 million versus the consensus estimate of $941.92 thousand.
For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Accenture shares fall on insider sales and analyst downgrade
- Verrica unlocks full $27.5M credit facility after hitting milestones
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
